EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Amiodarone and β‐blocker combination therapy versus β‐blocker monotherapy for ICD shock prevention: A meta‐analysis

Vahid Yazdi iD, Abdelmoniem Moustafa iD, Mohamad Nawras, Bayan Yazdi, Paul Chacko

Pacing and Clinical Electrophysiology · 2024

DOI: 10.1111/pace.15027 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Pacing and Clinical Electrophysiology, 2024. Verfasst von Vahid Yazdi und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Amiodarone, Adrenergic beta-Antagonists, Drug Therapy, Combination. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While implantable cardioverter‐defibrillator (ICD) shocks are a lifesaving therapy, they can negatively affect the patient's quality of life. Amiodarone is commonly combined with β‐blockers (BB) in ICD recipients. However, this combination therapy's efficacy in preventing shocks compared to standard BB monotherapy is not well studied. The aim of this systematic review and meta‐analysis is to determine if combined amiodarone and BB therapy improves prevention of ICD shock delivery compared to BB monotherapy. We performed a comprehensive literature search using PubMed, Cochrane, and Web of Science databases, for studies that assess the impact of amiodarone and BB versus BB monotherapy in patients with an ICD. The primary outcome was a total number of ICD shocks delivered by the end of the study period. Four studies: three retrospective studies and one randomized controlled trial (RCT), with a total of 5818 patients with ICDs, were included in the analysis. Follow‐up periods ranged from 1 to 5 years. The combined amiodarone and BB group was not associated with a significantly lower number of ICD shocks compared to the BB monotherapy group (OR, 0.76; 95% CI, 0.44‐1.31; P = .32). A combination therapy of amiodarone and BB was not associated with any further reduction in ICD shocks, hospitalizations, or mortality. Additional RCTs are recommended to further validate our findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Defibrillators, ImplantableAmiodaroneAdrenergic beta-AntagonistsDrug Therapy, CombinationAnti-Arrhythmia AgentsHumansTreatment Outcome

Stichwörter der Autor:innen

ICDamiodaroneβ‐blocker

Substanzen

AmiodaroneAdrenergic beta-AntagonistsAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
  • Department of Cardiovascular Medicine, University of Toledo, Toledo, Ohio, USA.
  • Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA.

ORCID-Profile: Vahid Yazdi, Abdelmoniem Moustafa

Zitieren

APA

Yazdi, V., Moustafa, A., Nawras, M., Yazdi, B., & Chacko, P. (2024). Amiodarone and β‐blocker combination therapy versus β‐blocker monotherapy for ICD shock prevention: A meta‐analysis. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.15027

Vancouver

Yazdi V, Moustafa A, Nawras M, Yazdi B, Chacko P. Amiodarone and β‐blocker combination therapy versus β‐blocker monotherapy for ICD shock prevention: A meta‐analysis. Pacing and Clinical Electrophysiology. 2024. doi:10.1111/pace.15027

BibTeX
@article{Yazdi2024,
  author = {Yazdi, Vahid and Moustafa, Abdelmoniem and Nawras, Mohamad and Yazdi, Bayan and Chacko, Paul},
  title = {Amiodarone and β‐blocker combination therapy versus β‐blocker monotherapy for ICD shock prevention: A meta‐analysis},
  journal = {Pacing and Clinical Electrophysiology},
  year = {2024},
  doi = {10.1111/pace.15027}
}
Kostenlos starten →